初诊伴有静脉血栓栓塞的晚期非小细胞肺癌的化疗疗效和安全性。

Efficacy and safety of chemotherapy for newly diagnosed advanced non-small cell lung cancer with venous thromboembolism.

机构信息

Beijing Institute of Respiratory Medicine, Beijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Beijing Chao-Yang Hospital, Capital Medical University Beijing, China ; Department of Respiratory Medicine, Beijing Shunyi District Hospital, China Medical University Beijing, China.

Beijing Institute of Respiratory Medicine, Beijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Beijing Chao-Yang Hospital, Capital Medical University Beijing, China.

出版信息

Thorac Cancer. 2015 Nov;6(6):772-7. doi: 10.1111/1759-7714.12278. Epub 2015 May 26.

DOI:10.1111/1759-7714.12278

PMID:26557917

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4632931/

Abstract

BACKGROUND

Venous thromboembolism (VTE) is a serious complication in patients with lung cancer. The benefit of chemotherapy for lung cancer patients with VTE remains unknown. This study was conducted to elucidate the efficacy and safety of chemotherapy for advanced non-small cell lung cancer (NSCLC) in patients with VTE.

METHODS

Newly diagnosed patients with advanced (i.e. stage IIIB and IV) NSCLC with VTE who received systemic chemotherapy were studied. Response rates, progression-free survival (PFS), overall survival (OS), and toxicity were retrospectively analyzed.

RESULTS

In this study, 21 patients who received chemotherapy plus anticoagulation therapy between December 2009 and February 2011 were included. The objective response and disease control rates within the first regimen were 14.29% (3/21) and 76.19 %(16/21), respectively. The median PFS, one-year survival rate, and median OS were 5.50 months, 33.30%, and 8.70 months, respectively. The main grade 3/4 toxicities observed included neutropenia (28.57%), nausea 4 (19.05%), and anemia 2 (9.52%). Major bleeding was not observed.

CONCLUSION

Chemotherapy for newly diagnosed patients with advanced NSCLC and VTE was feasible and had acceptable toxicity; however, the survival of these patients remained inferior to that of patients without VTE.

摘要

背景

静脉血栓栓塞症（VTE）是肺癌患者的严重并发症。VTE 患者接受化疗的获益尚不清楚。本研究旨在阐明 VTE 患者接受化疗治疗晚期非小细胞肺癌（NSCLC）的疗效和安全性。

方法

研究了 2009 年 12 月至 2011 年 2 月期间接受系统化疗联合抗凝治疗的初诊 VTE 晚期（即 IIIB 期和 IV 期）NSCLC 患者。回顾性分析了反应率、无进展生存期（PFS）、总生存期（OS）和毒性。

结果

本研究共纳入 21 例接受化疗联合抗凝治疗的患者。第一个疗程的客观缓解率和疾病控制率分别为 14.29%（3/21）和 76.19%（16/21）。中位 PFS、一年生存率和中位 OS 分别为 5.50 个月、33.30%和 8.70 个月。主要的 3/4 级毒性包括中性粒细胞减少症（28.57%）、恶心 4 例（19.05%）和贫血 2 例（9.52%）。未观察到大出血。